DK1372650T3 - Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat - Google Patents

Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat

Info

Publication number
DK1372650T3
DK1372650T3 DK02719992T DK02719992T DK1372650T3 DK 1372650 T3 DK1372650 T3 DK 1372650T3 DK 02719992 T DK02719992 T DK 02719992T DK 02719992 T DK02719992 T DK 02719992T DK 1372650 T3 DK1372650 T3 DK 1372650T3
Authority
DK
Denmark
Prior art keywords
epothilone
antidiarrheal agent
combinations containing
derivative
antidiarrheal
Prior art date
Application number
DK02719992T
Other languages
English (en)
Inventor
John David Rothermel
Horst F Schran
Diane Greeley
Tianling Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1372650T3 publication Critical patent/DK1372650T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02719992T 2001-03-19 2002-03-18 Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat DK1372650T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27715301P 2001-03-19 2001-03-19
US27720701P 2001-03-20 2001-03-20
PCT/EP2002/002977 WO2002074042A2 (en) 2001-03-19 2002-03-18 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative

Publications (1)

Publication Number Publication Date
DK1372650T3 true DK1372650T3 (da) 2009-03-16

Family

ID=26958333

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02719992T DK1372650T3 (da) 2001-03-19 2002-03-18 Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat

Country Status (27)

Country Link
US (1) US7030147B2 (da)
EP (1) EP1372650B1 (da)
JP (2) JP2004519493A (da)
KR (1) KR100863089B1 (da)
CN (1) CN100540001C (da)
AT (1) ATE414514T1 (da)
AU (1) AU2002251067B2 (da)
BR (1) BR0208142A (da)
CA (1) CA2440111C (da)
CY (1) CY1108845T1 (da)
CZ (1) CZ302848B6 (da)
DE (1) DE60229922D1 (da)
DK (1) DK1372650T3 (da)
ES (1) ES2318001T3 (da)
HK (1) HK1061516A1 (da)
HU (1) HUP0303621A3 (da)
IL (1) IL157333A0 (da)
MX (1) MXPA03008462A (da)
NO (1) NO333106B1 (da)
NZ (1) NZ541703A (da)
PT (1) PT1372650E (da)
RU (1) RU2330661C2 (da)
SI (1) SI1372650T1 (da)
SK (1) SK287334B6 (da)
TW (1) TWI331525B (da)
WO (1) WO2002074042A2 (da)
ZA (1) ZA200306318B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7018981B2 (en) * 2000-08-24 2006-03-28 Chugai Seiyaku Kabushiki Kaisha Cyclic motilin receptor antagonists
MXPA03008135A (es) 2001-03-14 2003-12-12 Bristol Myers Squibb Co Combinacion de analogos de epotilona y agentes quimioterapeuticos para tratamiento de enfermedades proliferativas.
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN102532120A (zh) 2002-08-23 2012-07-04 索隆-基特林癌症研究协会 埃坡霉素(epothilone)，合成埃坡霉素的中间体，其类似物及其用途
US7687625B2 (en) * 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1506967B1 (en) * 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
RU2253440C1 (ru) * 2004-03-31 2005-06-10 Открытое Акционерное Общество "Фаберлик" Средство для устранения нарушений нейрогенной и эндокринной регуляции системы капиллярного кровотока
EP1753730A1 (en) * 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
CN101535492A (zh) 2005-02-11 2009-09-16 南加州大学 表达含有二硫键的蛋白质的方法
EA015735B1 (ru) * 2005-09-14 2011-10-31 Такеда Фармасьютикал Компани Лимитед Фармацевтические композиции на основе 2-[[6-[(3r)-3-амино-1-пиперидинил]-3,4-дигидро-3-метил-2,4-диоксо-1(2н)-пиримидинил]метил]бензонитрила
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
KR20100096077A (ko) * 2007-11-09 2010-09-01 노파르티스 아게 에포틸론 또는 에포틸론 유도체 유발성 설사의 치료를 위한 코르티코스테로이드
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2011146638A1 (en) 2010-05-18 2011-11-24 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
KR101478925B1 (ko) * 2013-12-31 2015-01-08 아주대학교산학협력단 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
BR9710646A (pt) * 1996-03-12 2000-01-11 Pg Txl Co Lp Pródrogas de paclitaxel solúveis em água.
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6103487A (en) * 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
MXPA03008462A (es) 2003-12-08
JP2010006830A (ja) 2010-01-14
CN100540001C (zh) 2009-09-16
SK287334B6 (sk) 2010-07-07
CZ302848B6 (cs) 2011-12-14
KR100863089B1 (ko) 2008-10-13
IL157333A0 (en) 2004-02-19
US7030147B2 (en) 2006-04-18
NO20034094L (no) 2003-09-15
JP2004519493A (ja) 2004-07-02
CA2440111A1 (en) 2002-09-26
CY1108845T1 (el) 2014-07-02
ZA200306318B (en) 2005-02-23
NO333106B1 (no) 2013-03-04
SK11702003A3 (sk) 2004-02-03
WO2002074042A2 (en) 2002-09-26
CA2440111C (en) 2010-12-07
NO20034094D0 (no) 2003-09-15
SI1372650T1 (sl) 2009-04-30
CN1622805A (zh) 2005-06-01
CZ20032529A3 (cs) 2004-09-15
ES2318001T3 (es) 2009-05-01
PL363427A1 (en) 2004-11-15
RU2330661C2 (ru) 2008-08-10
TWI331525B (en) 2010-10-11
BR0208142A (pt) 2004-03-02
KR20040025907A (ko) 2004-03-26
NZ541703A (en) 2007-04-27
HK1061516A1 (en) 2004-09-24
HUP0303621A3 (en) 2005-03-29
ATE414514T1 (de) 2008-12-15
US20040092478A1 (en) 2004-05-13
PT1372650E (pt) 2009-02-25
WO2002074042A3 (en) 2003-02-27
HUP0303621A2 (hu) 2004-03-01
RU2003130058A (ru) 2005-04-10
EP1372650B1 (en) 2008-11-19
DE60229922D1 (de) 2009-01-02
EP1372650A2 (en) 2004-01-02
AU2002251067B2 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
DK1372650T3 (da) Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat
CY1112442T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1282611T3 (da) Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
AU2003237367A1 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
DK1446387T3 (da) Substituerede aryl, 1,4-pyrazinderivater
IL164249A0 (en) Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
NO20022528D0 (no) Kjemiske derivater og deres anvendelse som anti- telomerasemiddel
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
ITRM20020042U1 (it) Manico componibile perfezionato, in particolare manico per scope e simili.
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
IS6033A (is) Tálmar við amínótransferasa, sem háðir eru amínósýru með greinóttum keðjum, og notkun þeirra til meðhöndlunar á sjónusjúkdómum af völdum sykursýki
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
NO20021007L (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-oner og deres anvendelse som lipasehemmere
NO20043173L (no) Benzotiazol- og benzoksazol-4,7-dionderivater og deres anvendelse som CDC25-fosfataseinhibitorer
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
DK1239861T3 (da) Kombinationaf cyamemazin og et atypisk neuroleptikum